down arrow

Encompass Health Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29261A1007
USD
113.02
-0.02 (-0.02%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

111.96114.11

52 Week

87.85127.99
Valuation
Technical
Day's Volume

CASH

721.21 k

Shareholding (Mar 2025)

FII

15.27%

Held by 205 FIIs

DII

36.25%

Held by 61 DIIs

Promoter

0.11%

How big is Encompass Health Corp.?

22-Jun-2025

As of Jun 18, Encompass Health Corp. has a market capitalization of $13.73 billion, with net sales of $5.51 billion and a net profit of $653.6 million over the latest four quarters.

Market Cap: As of Jun 18, Encompass Health Corp. has a market capitalization of 13,733.69 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Encompass Health Corp. reported net sales of 5,512.60 million and a net profit of 653.60 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 2,067.00 million and total assets of 6,534.70 million.

Read More

What does Encompass Health Corp. do?

22-Jun-2025

Encompass Health Corporation provides post-acute healthcare services and operates in the mid-cap Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $1.455 billion and a net profit of $197 million, with a market cap of approximately $13.73 billion.

Overview:<BR>Encompass Health Corporation is a provider of post-acute healthcare services, operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 1,455 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 197 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 13,733.69 Million (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Dividend Yield: 35.89%<BR>- Debt Equity: 0.95<BR>- Return on Equity: 30.29%<BR>- Price to Book: 6.36<BR><BR>Contact Details:<BR>- Address: 9001 Liberty Pkwy, BIRMINGHAM AL: 35242-7509<BR>- Tel: 1 205 9677116<BR>- Website: https://www.encompasshealth.com/

Read More

Who are in the management team of Encompass Health Corp.?

22-Jun-2025

As of March 2022, the management team of Encompass Health Corp. includes Non-Executive Independent Chairman Leo Higdon, President and CEO Mark Tarr, and Independent Directors Gregory Carmichael, John Chidsey, Donald Correll, and Yvonne Curl, who oversee the company's strategic direction.

As of March 2022, the management team of Encompass Health Corp. includes the following individuals:<BR><BR>- Mr. Leo Higdon, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Mr. Mark Tarr, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Gregory Carmichael, who is an Independent Director.<BR>- Mr. John Chidsey, who is also an Independent Director.<BR>- Mr. Donald Correll, who serves as an Independent Director.<BR>- Ms. Yvonne Curl, who is an Independent Director. <BR><BR>This team is responsible for overseeing the strategic direction and management of the company.

Read More

Is Encompass Health Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Encompass Health Corp. is considered an attractive investment due to its undervaluation indicated by a P/E ratio of 21, a PEG ratio of 0.71, an EV to EBITDA ratio of 13.02, strong year-to-date performance of 34.87%, a high dividend yield of 35.19%, and a robust ROE of 30.29%.

As of 17 October 2025, the valuation grade for Encompass Health Corp. has moved from very expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, supported by a P/E ratio of 21, a PEG ratio of 0.71, and an EV to EBITDA ratio of 13.02. In comparison to peers, Encompass Health's P/E ratio is lower than The Ensign Group, Inc. at 32.46, but higher than DaVita, Inc. at 9.71, suggesting a competitive position within its industry.<BR><BR>The company's recent performance has outpaced the S&P 500, with a year-to-date return of 34.87% compared to the index's 13.30%. This strong performance, coupled with a high dividend yield of 35.19% and robust ROE of 30.29%, reinforces the attractiveness of the stock at its current valuation.

Read More

Is Encompass Health Corp. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Encompass Health Corp. has a mildly bullish trend, with mixed indicators showing mild bullishness on daily moving averages but mildly bearish signals on weekly MACD and KST, while it has underperformed the S&P 500 recently but outperformed it year-to-date.

As of 31 October 2025, the technical trend for Encompass Health Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a daily moving average indicating mild bullishness, while the weekly MACD and KST are both mildly bearish. The monthly RSI shows bullishness, and Bollinger Bands are bullish on the monthly timeframe but mildly bearish on the weekly. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -7.89% and -4.94% respectively, while it has outperformed the index year-to-date and over the longer term, with a YTD return of 26.84% compared to the S&P 500's 16.30%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 18.36%

 
2

Poor long term growth as Net Sales has grown by an annual rate of 4.26% and Operating profit at 9.42% over the last 5 years

 
3

The company has declared Positive results for the last 7 consecutive quarters

4

With ROCE of 21.99%, it has a very expensive valuation with a 3.82 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 14,505 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

23.73%

stock-summary
Debt Equity

0.89

stock-summary
Return on Equity

30.38%

stock-summary
Price to Book

6.36

Revenue and Profits:
Net Sales:
1,458 Million
(Quarterly Results - Jun 2025)
Net Profit:
185 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.21%
0%
-9.21%
6 Months
-6.8%
0%
-6.8%
1 Year
10.37%
0%
10.37%
2 Years
69.12%
0%
69.12%
3 Years
94.9%
0%
94.9%
4 Years
142.2%
0%
142.2%
5 Years
77.93%
0%
77.93%

Encompass Health Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Encompass Health Corp. technically bullish or bearish?

As of 31 October 2025, the technical trend for Encompass Health Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a daily moving average indicating mild bullishness, while the weekly MACD and KST are both mildly bearish. The monthly RSI shows bullishness, and Bollinger Bands are bullish on the monthly timeframe but mildly bearish on the weekly. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -7.89% and -4.94% respectively, while it has outperformed the index year-to-date and over the longer term, with a YTD return of 26.84% compared to the S&P 500's 16.30%....

Read More

Is Encompass Health Corp. technically bullish or bearish?

As of 31 October 2025, the technical trend for Encompass Health Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a monthly bullish MACD and RSI, while the weekly indicators show mixed signals with a mildly bearish MACD and Bollinger Bands. The daily moving averages indicate a mildly bullish trend. In terms of performance, Encompass Health has outperformed the S&P 500 year-to-date with a return of 25.68% compared to 16.30%, but has lagged over the past year with a return of 17.35% versus 19.89% for the index. Overall, the technical indicators suggest a cautious bullish outlook....

Read More

Is Encompass Health Corp. technically bullish or bearish?

As of 31 October 2025, the technical trend for Encompass Health Corp. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a mildly bearish stance, while the monthly indicators show bullish signals in MACD, RSI, and Dow Theory. The daily moving averages are mildly bullish, suggesting some short-term strength. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -9.74% and -8.57% respectively, while it has outperformed the benchmark year-to-date (23.28% vs. 16.30%) and over the longer three and five-year periods. Overall, the current technical stance is mildly bullish, driven by mixed signals across different time frames....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.26%
EBIT Growth (5y)
9.42%
EBIT to Interest (avg)
4.92
Debt to EBITDA (avg)
2.35
Net Debt to Equity (avg)
0.95
Sales to Capital Employed (avg)
1.21
Tax Ratio
18.96%
Dividend Payout Ratio
14.35%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
18.36%
ROE (avg)
27.24%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
6.49
EV to EBIT
17.37
EV to EBITDA
13.02
EV to Capital Employed
3.82
EV to Sales
2.91
PEG Ratio
0.71
Dividend Yield
35.19%
ROCE (Latest)
21.99%
ROE (Latest)
30.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 132 Schemes (48.3%)

Foreign Institutions

Held by 205 Foreign Institutions (15.27%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.16% vs 3.59% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -5.70% vs 20.61% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,457.70",
          "val2": "1,455.40",
          "chgp": "0.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "339.00",
          "val2": "346.20",
          "chgp": "-2.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "30.40",
          "val2": "31.80",
          "chgp": "-4.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "185.40",
          "val2": "196.60",
          "chgp": "-5.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "177.70%",
          "val2": "183.50%",
          "chgp": "-0.58%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.91% vs 10.41% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 26.24% vs 35.18% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,373.20",
          "val2": "4,801.20",
          "chgp": "11.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,164.10",
          "val2": "1,005.70",
          "chgp": "15.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "137.40",
          "val2": "143.50",
          "chgp": "-4.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "596.60",
          "val2": "472.60",
          "chgp": "26.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "160.90%",
          "val2": "152.40%",
          "chgp": "0.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1,457.70
1,455.40
0.16%
Operating Profit (PBDIT) excl Other Income
339.00
346.20
-2.08%
Interest
30.40
31.80
-4.40%
Exceptional Items
0.00
0.00
Consolidate Net Profit
185.40
196.60
-5.70%
Operating Profit Margin (Excl OI)
177.70%
183.50%
-0.58%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.16% vs 3.59% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -5.70% vs 20.61% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
5,373.20
4,801.20
11.91%
Operating Profit (PBDIT) excl Other Income
1,164.10
1,005.70
15.75%
Interest
137.40
143.50
-4.25%
Exceptional Items
-0.60
0.00
Consolidate Net Profit
596.60
472.60
26.24%
Operating Profit Margin (Excl OI)
160.90%
152.40%
0.85%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 11.91% vs 10.41% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 26.24% vs 35.18% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Encompass Health Corp. stock-summary
stock-summary
Encompass Health Corp.
Pharmaceuticals & Biotechnology
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 36 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. The Company manages its operations through segments, including inpatient rehabilitation, and home health and hospice. It is an owner and operator of inpatient rehabilitation hospitals. It provides specialized rehabilitative treatment on both an inpatient and outpatient basis. It offers its home health and hospice services through Encompass Home Health and Hospice business (Encompass). Encompass operates home health and hospice agencies in 30 states, with concentrations in the Southeast, Oklahoma, and Texas. As of December 31, 2018, the Company operated 130 inpatient rehabilitation hospitals.
Company Coordinates stock-summary
Company Details
9001 Liberty Pkwy , BIRMINGHAM AL : 35242-7509
stock-summary
Tel: 1 205 9677116
stock-summary
https://www.encompasshealth.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."